Hepatoprotective activity of a new germanium-organic biologically active substance (medgerm) in experimental hepatitis

Abstract

Aim. To study of the influence of new germanium-organic biologically active substance (medgerm) on lipid peroxidation and antioxidant system in rats with galactosamin-induced acute hepatitis. Methods. The experiments were carried out on Wistar male rats. Acute toxic hepatitis in rats was induced by intraperitoneal injection of D-galactosamine. Experimental animals were divided into 4 groups: first group (n=10) - intact animals that received 0.9% sodium chloride solution intraperitoneal injections throughout the observation period (control group); second group (n=40) - animals that received only D-galactosamine; third group (n=40) - rats that received medgerm intraperitoneal injections 7 days before and 7 days after the administration of D-galactosamine. The dose and administration regimen of medgerm were pre-defined. The fourth group (n=40) included rats that received Essentiale® N in the same mode as a comparator drug. Determination of thiobarbituric acid reactants, reduced glutathione levels in serum and liver homogenate supernatant, as well as superoxide dismutase and catalase activities were carried out in 1, 3, 5 and 7 days after the administration of liver toxins. Results. Medgerm has a significant effect on pro- and antioxidant homeostasis in acute toxic galactosamine-induced hepatitis. It effectively prevented the generation and accumulation of lipid peroxidation end products and preserved the activity of nonenzymatic and enzymatic antioxidant system parts. In animals treated with medgerm, studied parameters restored to reach the baseline level faster than in rats with galactosamine-induced hepatitis that were not treated with medgerm. Conclusion. The findings suggest that medgerm has the antioxidant activity and a membrane-mediated action in acute toxic hepatitis.

Keywords

germanium-organic substances / copper / medgerm / acute toxic hepatitis / antioxidant protection

References

[1] Буеверов А.О. Оксидативный стресс и его роль в повреждении печени // Рос. ж. гастроэнтерол., гепатол., колопроктол. - 2002. - №4. - С. 21-24.

[2] Ващенко В.И., Ващенко Т.Н. Церулоплазмин - от метаболита до лекарственного средства // Психофармакол. и биол. наркол. - 2006. - Т. 6, вып. 3. - С. 1254-1269.

[3] Годован В.В., Кресюн В.Й. Галактозаміновий гепатит як модель вивчення морфофункціональних порушень клітинних мембран // Одеський медичний ж. - 2005. - №3. - С. 11-15.

[4] Дзюба А.Н., Сорокин Ю.Н. Лечение рассеянного склероза и динамика антиоксидантного статуса // Укр. мед. часопис. - 2008. - №1. - С. 79-82.

[5] Лукевиц Э.Я., Гар Т.К., Игнатович Л.М. и др. Биологическая активность соединений германия. - Рига: Зинатне, 1990. - 191 с.

[6] Мазепа А.І., Мазепа первой. В. Роль міді та цинку в розвитку патології сполучної тканини // Медична хімія. - 2002. - Т. 4, №2. - С. 71-76.

[7] Оковитый С.В., Шуленини С.Н., Смирнов А.В. Клиническая фармакология антигипоксантов и антиоксидантов. - СПб.: ФАРМиндекс, 2006. - 70 с.

[8] Доклинические исследования лекарственных средств. Метод рекомендации / Под ред. А.В. Стефанова. - К.: ГФЦ МЗ Украины, 2002. - 567 с.

[9] Тимчишин О.Л., Кресюн В.Й., Годован В.В. і др. Гепатопротекторні властивості нової комплексної сполуки германію з купрумом (медгерму) при експериментальному токсичному гепатиті // Досягнення біології та медицини. - 2011. - №2. - С. 64-69.

[10] Ушкалова Е.А. Проблемы применения гепатопротекторов // Фарматека. - 2004. - №4. - С. 45-55.

[11] Юрьева Э.А., Матковская Т.А. О бисфосфонатах как о лекарственных соединениях (по материалам международного конгресса в Нидерландах, 2001) // Рос. вестн. перинатал. и педиатр. - 2001. - №3. - С. 59.

[12] Glorieux F.H. Experience with bisphosphonates in osteogenesis imperfecta // Pediatrics. - 2007. - Vol. 119, N 2. - P. 163-165.

[13] Lee J.H., Kim K.W., Yoon M.Y. et al. Antiinflammatory effect of germanium-concentrated yeast against paw oedema is related to the inhibition of arachidonic acid release and prostaglandin E production in RBL 2H3 cells // Auton. Autacoid. Pharmacol. - 2005. - Vol. 25,N 4. - P. 129-134.

[14] Massey P.B. Dietary supplements // Med. Clin. North Am. - 2002. - Vol. 86,N 1. - P. 127-147.

RIGHTS & PERMISSIONS

Tymchyshin O.L.